Accentia subsidiary Teamm to launch new pain product this quarter

By E. Janene Geiss

Philadelphia, Feb. 13 - Accentia Biopharmaceuticals Inc. said Monday that its manufacturing partner has received approval from the Food and Drug Administration for a unique combination pain product.

Teamm Pharmaceuticals, Inc., Accentia's wholly owned specialty pharmaceutical subsidiary, holds the exclusive U.S. license for the marketing and sales of this combination pain product and will launch the product in the first quarter of 2006, according to a company news release.

"This approval allows Teamm to expand our pain product portfolio, thus capitalizing on the franchise we started with Xodol (hydrocodone bitartrate and acetaminophen tablets, USP) 10 mg/300 mg," Gary Cantrell, Teamm executive vice president of sales and marketing, said in the release.

Xodol combines hydrocodone, a narcotic widely used for pain and the lowest effective dose of acetaminophen, the most commonly used analgesic, officials said.

This formula provides physicians with one of the most effective pain-management combinations, reducing the possibility that the patient will exceed the recommended daily allowance of acetaminophen.

The recommended daily dose of acetaminophen is up to 4,000 mg for a duration of less than 10 days and no more than 2,600 mg for longer-term use. Higher cumulative doses of acetaminophen have been shown to predispose patients to serious adverse effects including liver damage, officials said.

"An effective pain medication with a lower concentration of acetaminophen is an attractive option for physicians. As a result, our sales force has been highly successful in communicating the benefits of Xodol 10/300. The addition of our second combination pain product will allow us to expand our foothold in the pain market which generates more than 45 million prescriptions per year," Martin Baum, Teamm president and chief executive officer, said in the release.

Accentia is a Tampa, Fla., biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.